Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
NBY's Cash to Debt is ranked higher than
85% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. NBY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NBY' s 10-Year Cash to Debt Range
Min: 12.67  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.26
NBY's Equity to Asset is ranked lower than
88% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NBY: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
NBY' s 10-Year Equity to Asset Range
Min: -0.32  Med: 0.55 Max: 0.83
Current: 0.26
-0.32
0.83
Interest Coverage No Debt
NBY's Interest Coverage is ranked higher than
70% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NBY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NBY' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -14.90
M-Score: -3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1339.03
NBY's Operating margin (%) is ranked lower than
81% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. NBY: -1339.03 )
Ranked among companies with meaningful Operating margin (%) only.
NBY' s 10-Year Operating margin (%) Range
Min: -1601.33  Med: -119.61 Max: 17.47
Current: -1339.03
-1601.33
17.47
Net-margin (%) -1247.62
NBY's Net-margin (%) is ranked lower than
81% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. NBY: -1247.62 )
Ranked among companies with meaningful Net-margin (%) only.
NBY' s 10-Year Net-margin (%) Range
Min: -1441.56  Med: -101.15 Max: 17.2
Current: -1247.62
-1441.56
17.2
ROE (%) -264.60
NBY's ROE (%) is ranked lower than
93% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. NBY: -264.60 )
Ranked among companies with meaningful ROE (%) only.
NBY' s 10-Year ROE (%) Range
Min: -699.25  Med: -74.90 Max: 26.07
Current: -264.6
-699.25
26.07
ROA (%) -141.63
NBY's ROA (%) is ranked lower than
90% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. NBY: -141.63 )
Ranked among companies with meaningful ROA (%) only.
NBY' s 10-Year ROA (%) Range
Min: -426.46  Med: -42.83 Max: 17.13
Current: -141.63
-426.46
17.13
ROC (Joel Greenblatt) (%) -3537.48
NBY's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. NBY: -3537.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2925.13  Med: -729.34 Max: 139.97
Current: -3537.48
-2925.13
139.97
Revenue Growth (3Y)(%) -64.00
NBY's Revenue Growth (3Y)(%) is ranked lower than
87% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NBY: -64.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -40.20 Max: 36.1
Current: -64
0
36.1
EBITDA Growth (3Y)(%) 31.40
NBY's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. NBY: 31.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -19.60 Max: 58.2
Current: 31.4
0
58.2
EPS Growth (3Y)(%) 15.70
NBY's EPS Growth (3Y)(%) is ranked higher than
73% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. NBY: 15.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.1  Med: -2.10 Max: 56.5
Current: 15.7
-33.1
56.5
» NBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NBY Guru Trades in Q2 2014

Jim Simons 39,500 sh (New)
» More
Q3 2014

NBY Guru Trades in Q3 2014

Jim Simons 132,100 sh (+234.43%)
» More
Q4 2014

NBY Guru Trades in Q4 2014

Jim Simons 189,900 sh (+43.75%)
» More
Q1 2015

NBY Guru Trades in Q1 2015

Jim Simons 270,800 sh (+42.60%)
» More
» Details

Insider Trades

Latest Guru Trades with NBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 16.00
NBY's P/B is ranked lower than
90% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. NBY: 16.00 )
Ranked among companies with meaningful P/B only.
NBY' s 10-Year P/B Range
Min: 1.76  Med: 4.81 Max: 21.83
Current: 16
1.76
21.83
P/S 32.00
NBY's P/S is ranked lower than
67% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. NBY: 32.00 )
Ranked among companies with meaningful P/S only.
NBY' s 10-Year P/S Range
Min: 1.53  Med: 5.00 Max: 43.65
Current: 32
1.53
43.65
Current Ratio 2.05
NBY's Current Ratio is ranked lower than
74% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. NBY: 2.05 )
Ranked among companies with meaningful Current Ratio only.
NBY' s 10-Year Current Ratio Range
Min: 1.34  Med: 3.61 Max: 10.63
Current: 2.05
1.34
10.63
Quick Ratio 1.92
NBY's Quick Ratio is ranked lower than
71% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NBY: 1.92 )
Ranked among companies with meaningful Quick Ratio only.
NBY' s 10-Year Quick Ratio Range
Min: 1.34  Med: 3.61 Max: 10.63
Current: 1.92
1.34
10.63
Days Inventory 258.90
NBY's Days Inventory is ranked lower than
84% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. NBY: 258.90 )
Ranked among companies with meaningful Days Inventory only.
NBY' s 10-Year Days Inventory Range
Min: 104.77  Med: 221.93 Max: 524.69
Current: 258.9
104.77
524.69
Days Sales Outstanding 79.21
NBY's Days Sales Outstanding is ranked lower than
62% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. NBY: 79.21 )
Ranked among companies with meaningful Days Sales Outstanding only.
NBY' s 10-Year Days Sales Outstanding Range
Min: 0.1  Med: 65.93 Max: 94.54
Current: 79.21
0.1
94.54

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 22.00
NBY's Price/Net Current Asset Value is ranked lower than
80% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. NBY: 22.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NBY' s 10-Year Price/Net Current Asset Value Range
Min: 2.19  Med: 5.37 Max: 31.5
Current: 22
2.19
31.5
Price/Tangible Book 16.50
NBY's Price/Tangible Book is ranked lower than
84% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. NBY: 16.50 )
Ranked among companies with meaningful Price/Tangible Book only.
NBY' s 10-Year Price/Tangible Book Range
Min: 1.9  Med: 4.69 Max: 17.25
Current: 16.5
1.9
17.25
Price/Median PS Value 6.60
NBY's Price/Median PS Value is ranked lower than
95% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NBY: 6.60 )
Ranked among companies with meaningful Price/Median PS Value only.
NBY' s 10-Year Price/Median PS Value Range
Min: 0.33  Med: 1.00 Max: 8.4
Current: 6.6
0.33
8.4
Earnings Yield (Greenblatt) (%) -52.13
NBY's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NBY: -52.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NBY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.2  Med: 3.80 Max: 6.7
Current: -52.13
1.2
6.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
NovaBay Pharmaceuticals Inc was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc., and subsequently changed its name to NovaBay Pharmaceuticals, Inc. In June 2010, the Company was reincorporated under the laws of the state of Delaware. The Company is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with two distinct product categories, Aganocides, for the eye care market, NeutroPhase, for wound care, and CelleRx for the dermatology market; and clinical stage Aganocide Compounds. The Company is focusing its Aganocide compounds into three large therapeutic markets: Urology - Statistically- significant and clinically-meaningful results from a Phase 2 clinical study of Auriclosene Irrigation Solution to reduce urinary catheter blockage and encrustation, Ophthalmology - NovaBay is developing an eye drop formulation of auriclosene (NVC-422) for treating adenoviral conjunctivitis, for which there is currently no FDA-approved treatment, Dermatology - Partnered with Galderma, a dermatology company, the Company is developing a gel formulation of auriclosene (NVC-422) for treating impetigo, a contagious skin infection. The Company has also developed NeutroPhase, a distinct class of molecule from the Aganocides. NeutroPhase is an FDA 510(k)-cleared Advanced Skin and Wound Cleanser. It has developed variations of the NeutroPhase product such as i-Lid Cleanser and CelleRx. The competitors for its Aganocides and for NeutroPhase include large and small pharmaceutical and medical device companies, such as Pfizer, Inc., Johnson & Johnson, Abbott Grp. Plc., GlaxoSmithKline Plc, Sanofi-Aventis SA, Novartis AG, Smith & Nephew Plc, C.R. Bard, Molnlycke, Lohman and Roucher, Johnson and Johnson, 3M, Puricore and Oculus Innovative Sciences. The Company's Aganocide product candidate, auriclosene (NVC-422), as well as many of the product candidates they expect to develop in the future. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of its product candidates are subject to extensive regulation by the FDA, state agencies and comparable regulatory authorities in other countries.
» More Articles for NBY

Headlines

Articles On GuruFocus.com
Novabay Pharmaceuticals' CEO Dr. Ramin Najafi Interviewed by The Life Sciences Report Jun 25 2015 
Own it Feb 29 2012 
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results Aug 14 2009 

More From Other Websites
China Pioneer Pharma Offers Free NeutroPhase to Victims Suffered Burns in the Dust Explosion in... Jun 28 2015
Novabay Pharmaceuticals' CEO Dr. Ramin Najafi Interviewed by The Life Sciences Report Jun 25 2015
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 18 2015
Avenova Successfully Brings Relief to Patient with Challenging and Painful Eyelid Disease Jun 17 2015
NovaBay Pharmaceuticals Conference Call Today, June 9th, 2015, at 12:00 p.m. Eastern Time Jun 09 2015
NovaBay Pharmaceuticals Conference Call Today, June 9th, 2015, at 12:00 p.m. Eastern Time Jun 09 2015
Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System Jun 04 2015
FDA Clears NovaBay Pharmaceuticals’ New High-Tech Device, intelli-Case, for Safely Disinfecting... Jun 04 2015
FDA Clears NovaBay Pharmaceuticals’ New High-Tech Device, intelli-Case, for Safely Disinfecting... Jun 04 2015
Panning for Golden Stocks Outside the Gold Industry May 28 2015
SeeThruEquity Initiates Coverage on NovaBay Pharmaceuticals with a Price Target of $1.87 May 27 2015
Doctors Embrace Avenova™ for Common Eye Conditions May 27 2015
NOVABAY PHARMACEUTICALS, INC. Financials May 22 2015
NovaBay Announces $6.86 Million “At Market” Private Placement May 22 2015
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 22 2015
NovaBay Announces $6.86 Million “At Market” Private Placement May 22 2015
10-Q for NovaBay Pharmaceuticals, Inc. May 17 2015
NovaBay Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update May 14 2015
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 14 2015
NovaBay Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK